EMA Application withdrawn: Gefzuris (gefapixant) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA reports that the application for Gefzuris (gefapixant) by Merck Sharp & Dohme B.V. has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefzuris (gefapixant)

Snippet

Status: Application withdrawn. Therapeutic area: Cough. MAH: Merck Sharp & Dohme B.V.